XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer
Journal of Clinical Oncology
Vol 22, No 11 (June 1), 2004: pp. 2084-2091
Jim Cassidy, Josep Tabernero, Chris Twelves, René Brunet, Charles Butts, Thierry Conroy, Filippo Debraud, Arie Figer, Johannes Grossmann, Noriaki Sawada, Patrick Schöffski, Alberto Sobrero, Eric Van Cutsem, Eduardo Díaz-Rubio
DOI: 10.1200/JCO.2004.11.069
Go to journal article.
Journal Article: Xelox and Colorectal Cancer
Cancer Research - June 2004
From Donna Myers, former About.com Guide
Updated: August 5, 2005
About.com Health's Disease and Condition content is reviewed by the Medical Review Board
Related Articles
- Oxaliplatin-Based Chemotherapy in Association with Highly Active Antiretrov...
- BRCA Mutations May Not Increase Colon Cancer Risk
- Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer
- Hepatic Expression of ANG2 RNA in Metastatic Colorectal Cancer
- An Increasingly Common Challenge: Management of the Complete Responder With...
Related Searches alberto sobrero journal of clinical oncology jim cassidy colorectal cancer cancer journal van cutsem
Explore Colon Cancer
- About.com
- Health
- Colon Cancer
- Basics
- Research Articles
- Journal Article Abstracts
- Journal Articles from 2004
- XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer
